Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose CNS-penetrating chemotherapy plus intrathecal liposomal cytarabine followed by high-dose chemotherapy and autologous stem cell transplantation for CNS relapse of aggressive lymphoma
2006-006516-30Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, ifosfamide, cytarabine, thiotepa, liposomal cytarabine and 2 more in non-Hodgkin lymphoma (NHL) and central nervous system lymphoma, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Time to treatment failure. Started Apr 2007; status: completed.
02
Drugs
methotrexateifosfamidecytarabinethiotepaliposomal cytarabine
03
Conditions
non-Hodgkin lymphoma (NHL)central nervous system lymphoma
Beyond the preview
Go deeper on 2006-006516-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006516-30.